Form 4 Filing for Cadrenal Therapeutics, Inc.

This filing details transactions by Pham Quang X, Chairman, CEO, and Interim CFO of Cadrenal Therapeutics, Inc. On June 16, 2026, 3613 shares of common stock were sold at a weighted average price of $3.18, with individual sales ranging from $3.04 to $3.37, under a Rule 10b5-1 trading arrangement. Following this, 129102 shares remained. On June 17, 2026, an additional 513 shares were sold at a weighted average price of $3.16, with prices ranging from $3.14 to $3.20, also under the Rule 10b5-1 arrangement. This left 128589 shares. The filing also notes that Pham Quang X, as Trustee of The PVBQ Living Trust, has voting and disposal power over shares held by the trust, which are for the benefit of his child. The trust holds 200000 shares.